Macquarie Group’s ImmunityBio IBRX Stock Holding History

Macquarie Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,800	Closed	-$7K	–	1831
2018 Q4	$7K	Buy	5,800 +4,900	+544%	+$11.2K	﹤0.01%	1999
2018 Q3	$3K	Sell	900 -2,400	-73%	-$7.59K	﹤0.01%	2109
2018 Q2	$10K	Buy	+3,300	New	+$12.2K	﹤0.01%	2125
2018 Q1	–	Sell	-1,500	Closed	-$7K	–	2249
2017 Q4	$7K	Buy	+1,500	New	+$7.1K	﹤0.01%	2331

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Macquarie Group's IBRX Position: Q1 2019 in Review

Macquarie Group sold out of ImmunityBio (IBRX) in Q1 2019, closing a stake of 5,800 shares — an estimated $7K sold.

Macquarie Group first reported a position in IBRX in Q4 2017 and held it in 4 quarters. The position peaked at $10K in Q2 2018. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

Macquarie Group reported no remaining ImmunityBio position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 5,800 ImmunityBio shares in Q1 2019, an estimated $7K.
Macquarie Group first reported a position in ImmunityBio in Q4 2017 and held it in 4 quarters.
Macquarie Group's ImmunityBio position peaked at $10K in Q2 2018.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.